Triangle Business Journal – As BioDelivery Sciences International awaits approval of its first product, a New York hedge fund has gained control of enough BDSI shares to become its largest shareholder.
With what looks like one goal in mind – making a lot of money.
Elliott International Capital Advisors is the same firm that tried to shake up Raleigh-based BDSI with a management change two years ago. That was at a time when the company was developing Onsolis, a small disk placed on the inside of the cheek that quickly delivers the drug fentanyl to cancer patients suffering breakthrough pain.
